Education
About Us
Working with TipRanks
Follow Us
Antibe Therapeutics, Inc. (Otc) (ATBPF)
:ATBPF
Total Valuation
Antibe Therapeutics has a market cap or net worth of $7.42M. The enterprise value is ―.
Market Cap$7.42M
Enterprise Value―
Share Statistics
Antibe Therapeutics has 52,651,260 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding52,651,260
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Antibe Therapeutics’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.
Return on Equity (ROE)―
Return on Assets (ROA)―
Return on Invested Capital (ROIC)―
Return on Capital Employed (ROCE)―
Revenue Per Employee0.00
Profits Per Employee-1.77M
Employee Count11
Asset Turnover―
Inventory Turnover―
Valuation Ratios
The current PE Ratio of Antibe Therapeutics is ―. Antibe Therapeutics’s PEG ratio is ―.
PE Ratio―
PS Ratio―
PB Ratio―
Price to Fair Value―
Price to FCF―
Price to Operating Cash Flow―
PEG Ratio―
Income Statement
In the last 12 months, Antibe Therapeutics had revenue of 0.00 and earned -19.48M in profits. Earnings per share was -0.37.
Revenue0.00
Gross Profit0.00
Operating Income-20.55M
Pretax Income-19.29M
Net Income-19.48M
EBITDA-19.19M
Earnings Per Share (EPS)-0.37
Cash Flow
In the last 12 months, operating cash flow was -18.25M and capital expenditures 2.00K, giving a free cash flow of -18.24M billion.
Operating Cash Flow-18.25M
Free Cash Flow-18.24M
Free Cash Flow per Share-0.35
Dividends & Yields
Antibe Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.93
52-Week Price Change0.00%
50-Day Moving Average0.22
200-Day Moving Average0.22
Relative Strength Index (RSI)100.00
Average Volume (3m)0.00
Important Dates
Antibe Therapeutics upcoming earnings date is Feb 12, 2025, TBA Not Confirmed.
Last Earnings DateNov 11, 2024
Next Earnings DateFeb 12, 2025
Ex-Dividend Date―
Financial Position
Antibe Therapeutics as a current ratio of ―, with Debt / Equity ratio of ―
Current Ratio―
Quick Ratio―
Debt to Market Cap―
Net Debt to EBITDA―
Interest Coverage Ratio―
Taxes
In the past 12 months, Antibe Therapeutics has paid 184.00K in taxes.
Income Tax184.00K
Effective Tax Rate―
Enterprise Valuation
Antibe Therapeutics EV to EBITDA ratio is ―, with an EV/FCF ratio of ―.
EV to Sales―
EV to EBITDA―
EV to Free Cash Flow―
EV to Operating Cash Flow―
Balance Sheet
Antibe Therapeutics has $24.91M in cash and marketable securities with C$0.00 in debt, giving a net cash position of -$24.91M billion.
Cash & Marketable Securities$24.91M
Total DebtC$0.00
Net Cash-$24.91M
Net Cash Per Share-$0.47
Tangible Book Value Per Share―
Margins
Gross margin is ―, with operating margin of ―, and net profit margin of ―.
Gross Margin―
Operating Margin―
Pretax Margin―
Net Profit Margin―
EBITDA Margin―
EBIT Margin―
Analyst Forecast
The average price target for Antibe Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―